# A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

> **NCT05735483** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Eli Lilly and Company** · enrollment: 310 (estimated)

## Conditions studied

- Atopic Dermatitis
- Eczema

## Interventions

- **DRUG:** Lebrikizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05735483
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-03-09
- **Primary completion:** 2027-12
- **Final completion:** 2029-04
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735483, "A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05735483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*